HomeIndustriesHealthcareOverlooked Stock: HIMS

Overlooked Stock: HIMS

Hims & Hers Health (HIMS) sold off most of its massive rally today that it got over the last couple weeks. George Tsilis points out that the FDA no longer sees shortages of Novo Nordisk's (NVO) Ozempic and Wegovy weight loss drugs. Hims & Hers creates a similar product, but George says there's more to the selling action when you turn to its earnings.

Market On Close

21 Feb 2025

SHARE

ON AIR
education
9:00 am
Your First Trade
replay
12:00 am
Trading 360
REPLAY
1:00 am
Fast Market
REPLAY
2:00 am
Next Gen Investing
REPLAY
education
3:00 am
Your First Trade
REPLAY
education
3:30 am
Inside the Mind of a Trader
REPLAY
education
4:00 am
Inside the Mind of a Trader
REPLAY
education
4:30 am
Inside the Mind of a Trader
REPLAY
education
5:00 am
Your First Trade
REPLAY
education
5:30 am
Your First Trade
REPLAY
6:00 am
Market Overtime
REPLAY
education
7:00 am
Inside the Mind of a Trader
REPLAY
education
7:30 am
Inside the Mind of a Trader
REPLAY
education
8:00 am
Inside the Mind of a Trader
REPLAY
8:30 am
Market Overtime
REPLAY
ON AIR
education
9:00 am
Your First Trade
REPLAY
education
9:30 am
Your First Trade
REPLAY
education
10:00 am
Your First Trade
REPLAY
education
10:30 am
Your First Trade
REPLAY
education
11:00 am
Your First Trade
REPLAY
education
11:30 am
Your First Trade
REPLAY
education
12:00 pm
Your First Trade
REPLAY
education
12:30 pm
Your First Trade
REPLAY
education
1:00 pm
Your First Trade
REPLAY
education
1:30 pm
Your First Trade
REPLAY
2:00 pm
Trading 360
REPLAY
3:00 pm
Fast Market
REPLAY
4:00 pm
Next Gen Investing
REPLAY
5:00 pm
Market Overtime
REPLAY
education
5:30 pm
Inside the Mind of a Trader
REPLAY
education
6:00 pm
Inside the Mind of a Trader
REPLAY
education
6:30 pm
Inside the Mind of a Trader
REPLAY
7:00 pm
Market Overtime
REPLAY
8:00 pm
Market Overtime
REPLAY
8:30 pm
Market Overtime
REPLAY
9:00 pm
Trading 360
REPLAY
10:00 pm
Fast Market
REPLAY
11:00 pm
Next Gen Investing
REPLAY

Schwab Network's Newsletters

Daily insights for every investor